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Abstract 
Background: Newly proliferated oligodendrocyte precursor cells (OPCs) migrate and surround lesions of patients 
with multiple sclerosis (MS) and other demyelinating diseases, but fail to differentiate into oligodendrocytes (OLs) and 
remyelinate remaining viable axons. The abundance of secreted inflammatory factors within and surrounding these 
lesions likely plays a major inhibitory role, promoting cell death and preventing OL differentiation and axon remyelina‑
tion. To identify clinical candidate compounds that may protect existing and differentiating OLs in patients, we have 
developed a high throughput screening (HTS) assay that utilizes purified rat OPCs.
Results: Using a fluorescent indicator of cell viability coupled with image quantification, we developed an assay to 
allow the identification of compounds that promote OL viability and differentiation in the presence of the synergistic 
inflammatory cytokines, tumor necrosis factor α and interferon‑γ. We have utilized this assay to screen the NIH clinical 
collection library and identify compounds that protect OLs and promote OL differentiation in the presence of these 
inflammatory cytokines.
Conclusion: This primary OL‑based cytokine protection assay is adaptable for HTS and may be easily modified for 
profiling of compounds in the presence of other potentially inhibitory molecules found in MS lesions. This assay 
should be of use to those interested in identifying drugs for the treatment of MS and other demyelinating diseases.
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Background
Multiple sclerosis (MS) is a devastating neurological dis-
ease, affecting over 2 million patients worldwide, caused 
by autoimmune-mediated destruction of the myelin 
sheaths that insulate and protect axons in the central 
nervous system. Most MS patients initially present with 
the relapsing-remitting form of MS relapsing remitting 
multiple sclerosis (RRMS), in which cycles of immune-
mediated axonal demyelination (relapse) are followed by 
periods of remyelination (remission). Over time, how-
ever, the majority of RRMS patients exhibit chronic, pro-
gressive decline in neurological function. This is believed 
to be the result of an accumulation of axonal damage, 
as well as an eventual loss of remyelination capacity 
[1]. Although current MS therapies for RRMS provide 
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significant relief from relapse, none have yet been dem-
onstrated to prevent disease progression and none have 
been effective in treating progressive forms of MS. All 
of the disease-modifying therapies approved for treat-
ment of RRMS do so by targeting the pathologic immune 
response [2]. There are no therapies that function to 
directly protect or restore myelin, and identifying such 
therapies has been the focus of several groups in the field 
[3–6].
One approach undertaken by several groups seek-
ing to identify new therapeutic agents, has been to 
screen small molecule libraries in an attempt to iden-
tify agents that accelerate differentiation of immature 
oligodendrocyte precursor cells (OPCs) into mature, 
myelin-producing oligodendrocytes (OLs) in the hope 
that this will accelerate remyelination of axons follow-
ing immune attack. While it is logical to expect that 
increasing the number of mature oligodendrocytes 
will improve the rate and extent of axonal remyelina-
tion, it should be considered that the oligodendrocyte 
differentiation assays described above assess differen-
tiation of OPCs into oligodendrocytes under healthy 
conditions. MS lesions contain a number of factors 
that are known to impair oligodendrocyte differentia-
tion and reduce the viability of differentiating oligoden-
drocytes. We thus felt that it was important to develop 
assays useful for the identification of drugs that sup-
port oligodendrocyte differentiation under conditions 
mimicking disease. We therefore examined the effects 
of interferon-γ (IFNγ) in the presence tumor necrosis 
factor α (TNFα), a combination shown to be synergis-
tically deleterious for other cell types in culture [7]. 
We observed that addition of TNFα alone had no ill 
effects on oligodendrocyte differentiation or viability. 
However, the presence of TNFα substantially increased 
the deleterious effects of IFNγ on both differentiation 
and viability of cultured oligodendrocytes, and did so 
at cytokine concentrations that were low enough to be 
relevant to the in  vivo disease state. Using this infor-
mation, we developed an assay suitable for rapid high 
throughput screening, to identify drugs that protect 
differentiating oligodendrocytes from cytokine toxicity. 
We used this assay to screen the NIH clinical collection 
(NCC) library (a library of 727 drugs that have been 
approved for the treatment of various indications), and 
report here the identification of several FDA-approved 
drugs that sustain viability and differentiation capacity 
of oligodendrocytes in the presence of IFNγ and TNFα 
in  vitro. This assay will be useful for screening novel 
compound libraries and is adaptable to screening com-
pounds in the presence of other factors present in MS 
lesions.
Findings
Development of an oligodendrocyte protection assay 
in the presence of inflammatory cytokines
We developed an assay to identify compounds that would 
protect differentiating OLs under adverse conditions, 
such as those present in MS lesions. Pro-inflammatory 
cytokines are known to have detrimental effects on OL 
differentiation and viability [8–11] and thus we incor-
porated the adverse challenge of two prominent compo-
nents of the inflammatory cascade, TNFα and IFNγ, into 
our assay conditions. TNFα has been demonstrated to 
be present in MS lesions along with IFNγ and its expres-
sion levels change during different stages of the disease 
[12–14].
In vitro expanded OPCs were plated in PDL-coated 
96-well plates at 10,000 cells/well in differentiation media 
supplemented with T3, but without PDGF in order to 
promote OL differentiation. These minimally expanded 
OPCs differentiated into OLs within 3 days in the pres-
ence of T3 as determined by imaging of MBP expression 
(Figs. 1A, 2D).
To determine the effects of inflammatory cytokines on 
actively differentiating OLs, we initially tested the effects 
of exposure to IFNγ alone on the viability of T3-induced 
differentiating OLs, an insult previously shown to cause 
apoptosis of OLs [8]. Following 48  h of IFNγ exposure, 
the viability of cells was determined by alamarBlue® 
(AB—a fluorescent indicator of metabolic activity) fluo-
rescence quantification. At least 200  Units/ml of IFNγ 
was required to generate a 20 % reduction in differenti-
ating OL viability when added alone (Fig.  1B). We used 
this concentration to test whether we could identify 
small molecules that could rescue OLs from IFNγ tox-
icity. We tested the confirmed hit compounds identified 
in an acute OL differentiation assay (see [15]). We added 
test compounds 24  h following OPC plating and 1  h 
prior to the addition of INFγ insult to give compounds 
the best chance for efficacy; cells were assayed 48 h later 
for viability with AB. Since AB fluorescence is produced 
by incubation with live cells and is non-toxic, we were 
able to wash, fix, and immunostain the same cultures for 
MBP expression (see “Methods” section) and quantify 
MBP expression. Figure 1A shows the decrease in MBP 
immunostaining intensity caused by 200  U/ml IFNγ. 
Additional file  1: Table S1 includes the EC50 values for 
protection from IFNγ-induced toxicity and restoration of 
OL differentiation (image quantification of MBP expres-
sion—see [15]) calculated for each compound tested. 
Figure  1C shows the dose response relationship of OL 
protection from toxicity induced by 200  Units/ml IFNγ 
of one of the most efficacious compounds tested, quetia-
pine (QTP). 1.1 µM QTP was determined to be the most 
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efficacious concentration in protecting OLs from IFNγ 
toxicity (Fig.  1B) as well as for preserving MBP expres-
sion (Fig. 1C).
In an attempt to increase the cytokine protection win-
dow, we tested TNFα alone, up to 20 ng/ml, which had no 
measurable impact on viability of OLs (Fig. 2A). Since it 
is known that IFNγ and TNFα can combine to have syn-
ergistic effects and are both present in MS lesions [8, 16], 
we titrated each cytokine against the other to determine 
possible synergistic effects for use in the OL protection 
assay. When TNFα was titrated against a fixed concen-
tration of 100  U/ml IFNγ, the combination of 100  U/
ml IFNγ  +  1.25  ng/ml TNFα resulted in a drop in OL 
viability of 46 % vs. only 11 % for 100 Units/ml of IFNγ 
alone (Fig. 2A). To further optimize the synergistic com-
bination of TNFα and IFNγ we narrowed the range of 
concentrations and measured both OL viability and dif-
ferentiation. We were able to titrate IFNγ down to 10 U/
ml in combination with 1  ng/ml TNFα and still repro-
ducibly obtain ~30 % reduction of OL viability (Fig. 2B, 
E). This cytokine combination also resulted in  ~50  % 
reduction in OL differentiation as determined by quan-
tification of MBP expression (Fig. 2C–E). Concentrations 
of TNFα above 1 ng/ml resulted in toxicity that reduced 
MBP to undetectable levels.
We used this newly developed cytokine protection 
assay (TNFα +  IFNγ) to evaluate the activity of the hit 
compounds identified in the acute OL differentiation 
screen (see [15]). We generated dose response curves and 
EC50 values for each compound for viability and OL dif-
ferentiation (Additional file 2: Figure S1; Table 1). Addi-
tionally, Additional file  2: Figure S1 shows the chemical 
structures of confirmed hit compounds and representa-
tive MBP/DAPI images taken from the screen. All com-
pounds that rescued OL differentiation also increased 
cell viability. However, three compounds were nega-
tive for viability promoting activity, showing very lit-
tle cytokine protection activity or OL differentiation 
(<20 % rescue; citalopram, esmolol, and dofetilide). One 
class of compounds having anti-fungal activity (bifona-
zole, clotrimazole, econazole) sustained viability of OLs 
but did not preserve OL differentiation in the presence 
Fig. 1 IFNγ reduces OL viability and inhibits differentiation. A Expanded OPCs were plated in 96 well plates in DMEM differentiation media for 24 h 
and either treated for 1 h with 1.1 µM quetiapine (QTP) or vehicle (0.1 % DMSO), followed by 48 h of 200 U/ml INFγ insult. No Insult was vehicle 
treated with no IFNγ insult. OLs were immunostained for MBP (green) and nuclei stained with DAPI (blue). Bar 200 μM. B 24 h after plating, differen‑
tiating OLs were treated with increasing concentrations of INFγ for 48 h. alamarBlue® (AB) fluorescence was quantified to determine cell viability. C 
24 h after plating, differentiating OLs were treated with increasing concentrations of QTP for 1 h followed by 48 h treatment with 200 U/ml IFNγ. Cell 
viability was measured by quantification of alamarBlue® fluorescence. Image quantification of anti‑MBP immunostaining of the same cultures was 
used to measure OL differentiation
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of cytokines (Additional file 2: Figure S1F1, S1G1, S1H1). 
This indicates that the mechanism of cytokine protection 
can be separated from the promotion of differentiation in 
the presence of inflammatory cytokines.
We then assessed the ability of QTP to protect OLs 
from the combined 1  ng/ml TNFα and 10U/ml IFNγ 
toxicity. QTP preserved OL differentiation in the pres-
ence of both 1 ng/ml TNFα and 10 U/ml IFNγ demon-
strated by imaging of MBP immunostaining (Fig.  3A). 
Figure  3B, C shows the dose–response relationships 
for QTP in both parameters of the cytokine protection 
assay. The EC50 values were determined to be 157  nM 
for viability protection and 125  nM for OL differentia-
tion protection. From this data, we chose 1.1  µM as a 
positive control assay concentration to be used in subse-
quent assay screens. 1.1 µM QTP reproducibly rescued 
differentiating OLs from cytokine-induced toxicity by an 
average of 90 % (Fig. 3D) and restored their ability to dif-
ferentiate by 60 % (Fig. 3E).
NCC Library screening for compounds that protect 
differentiating OLs from combined INFγ and TNFα insult
Prior to library screening, NCC library compounds were 
prescreened at three concentrations for OL toxicity (see 
[15]). This allowed for the reduction of toxic concentra-
tions and to potentially detect active compounds active 
at lower doses.
To reduce time, reagent and labor costs, we decided 
to screen the NCC library using the viability detection 
portion of the cytokine protection assay, as we observed 
that OL differentiation was only rescued if cell viability 
was rescued in profiling the hits from the acute OL dif-
ferentiation assay. Figure 4 shows the flow scheme for the 
cytokine protection assay. OPCs were purified, expanded 
in the presence of PDGF and plated in 96 well plates as 
described above. Differentiation was initiated by PDGF 
withdrawal and T3 supplementation. Following a 24-h 
incubation period, test compounds were added (at two 
different concentrations initially determined from the 
Fig. 2 TNFα synergizes with IFNγ causing reduced OL survival and inhibiting differentiation. Expanded OPCs were plated in DMEM differentiation 
media for 24 h and then treated with various combinations cytokines for 48 h. A Differentiating OLs were treated with increasing concentrations 
of TNFα alone (gray bars) or increasing concentrations of TNFα + 100 U/ml INFγ (black bars) and alamarBlue® (AB) fluorescence was quantified to 
determine cell viability. B Cells were treated as in A with increasing concentrations of TNFα alone (black bars) or TNFα + 5, 10, or 20 U/ml INFγ (light 
gray, dark gray, or white bars respectively) and AB fluorescence was quantified to determine cell viability. C Image quantification of anti‑MBP immu‑
nostaining of the same cultures as in B was used to measure OL differentiation. D Comparison of MBP expression in untreated (No insult) or 10 U/
ml INFγ + 1 ng/ml TNFα treated differentiating OLs. E Viability and OL differentiation raw values of no insult versus 10 U/ml INFγ + 1 ng/ml TNFα 
demonstrate the reproducibility of the combined cytokine toxicity. Coefficient of variation (CV) values for cell viability were 7.47 and 6.14 % and for 
OL differentiation were 11.37 and 19.16 % for No insult or TNFα+INFγ, respectively. CV values <20 % were considered in the acceptable range
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OL toxicity assay) followed 1 h later by addition of 1 ng/
ml TNFα + 10 U/ml IFNγ. After 48-h incubation in the 
presence of cytokines, AB was added to cells and the 
fluorescence quantified to determine cell viability. Each 
compound concentration was screened in triplicate with 
data scaled relative to 0.1 % DMSO as the negative con-
trol and 1.1 µM QTP as the positive control. A no insult 
control was also included to assess the consistency of 
cytokine toxicity.
The criterion for a hit compound was protection of dif-
ferentiating OLs from cytokine toxicity that was at least 
50 % of the positive control, 1.1 µM QTP level or above. 
Similar to the OL differentiation assay, we included in our 
analysis the visualization of three SDs above the mean 
Table 1 Confirmed cytokine protection hits from the NCC library screen
LO lipooxygenase
a Hit in acute OL differentiation assay (as determined in [15])
b Inconsistent, weak OL differentiation activity
c Not in NCC library
Drug class Compound AB screening  
(% quetiapine)
AB EC50 (μM) MBP EC50 (μM) Hit in OL diff
a
SERM Raloxifene 92 0.03 0.05 •
Toremifene 73 0.02 0.01 •
Tamoxifen 117 0.02 0.01 •
Mestranol 93 0.92 0.79
Clomiphene 52 0.01 0.01
Tricyclic anti‑depressants Perphenazine 96 0.01 0.03 •
Fluphenazine 91 0.02 0.02 •
Prochlorperazine 110 0.04 0.04 •
Trifluoperazine 155 0.02 0.03 •
Quetiapine 130 0.15 0.13 •
Non‑tricyclic anti‑depressants Perospirone 85 0.22 0.15 •
Bupropion 71 3.89 3.86 •
Bifemelane 78 0.20 0.26
Cinanserin 64 0.97 1.59
Trazadone 55 7.18 5.42
Muscarinic Clemastinec 0.14 0.14 •
Benztropine 123 0.17 0.14 •
Donepezil 95 0.46 0.74 •
Vesamicol 151 1.83 2.26 •
Oxybutynin 92 0.67 0.54 •
Propantheline 91 2.95 1.25
Adrenergic Salmeterol 55 0.22 0.20 •
Betaxolol 52 5.56 6.21 •
Ion channel Ifenprodil 162 0.36 0.52 •
Benproperine 99 0.43 0.12 •
Proxymetacaine 98 1.23 0.78 •
DMPP 54 2.18 2.84 •
Anti‑fungal Bifonazole 105 0.44 b •
Clotrimazole 171 0.77 b
Econazole 90 0.34 b
Antidiabetic Pioglitazone 56 7.34 b
LO inhibitor MK886 51 0.31 0.19
Histamine H1 Antagonists Hydroxyzine Pamoate 106 0.15 0.11
Meclizine 97 0.12 0.10
Retinoids All‑trans‑retinoic acid 128 0.88 0.44
Acitretin 69 2.23 1.09
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(Fig. 5A). Alongside this, we show the 50 % QTP thresh-
old line (Fig.  5A). Control QTP versus DMSO values 
from the entire screen for OL differentiation were highly 
statistically significant per assay plate (Fig. 5B, C) as well 
as when averaged over entire screen (Fig. 5C, inset) indi-
cating an acceptable screen window and reproducibility. 
In a screen of 727 FDA-approved drugs, we identified 44 
actives (6 % primary hit rate) able to protect differentiat-
ing OLs from cytokine toxicity at one or both concentra-
tions tested (Fig. 5D). Additional file 3: Table S2 includes 
the data for all compounds tested in the cytokine protec-
tion screen.
Independent confirmation and validation of identified hits
In order to confirm the activity of the primary hits iden-
tified in the cytokine protection assay, we purchased 40 
fresh compounds from independent vendors and per-
formed a dose response analyses (4 compounds were 
excluded from follow up). We confirmed 36 active com-
pounds (90 % hit confirmation rate) and determined the 
EC50 values for both viability (AB fluorescence quantifi-
cation) and OL differentiation (quantification of MBP 
immunostaining) protection in the presence of inflam-
matory cytokines (Table 1).
Discussion
In an effort to identify possible therapeutic candidate 
compounds for multiple sclerosis and other demyeli-
nating diseases, we have established a high throughput 
assay that can be used to rapidly screen large compound 
libraries for molecules that protect differentiating OLs 
from the deleterious effects of inflammatory cytokines. 
We reasoned that the differentiation and viability of OLs 
at the site of a demyelinating lesion may be compro-
mised as a result of exposure to a variety of inhibitory 
and/or toxic stimuli, including inflammatory cytokines. 
We used this assay to screen the NCC library, assessing 
each compound’s ability to protect differentiating OLs 
from the combinatorial effect of INFγ and TNFα tox-
icity. We identified and confirmed 35 hit compounds 
establishing their potency and efficacy. To the best of 
our knowledge, this is the first high-throughput screen 
designed for the purpose of assessing OL differentiation 
and survival of differentiating OLs under inflammatory 
Fig. 3 Quetiapine (QTP) reproducibly rescues viability and OL differentiation in the presence of cytokine‑mediated toxicity. Expanded OPCs were 
plated in 96 well plates in DMEM differentiation media for 24 h and either treated for 1 h with 1.1 µM quetiapine or 0.1 % DMSO vehicle, followed 
by 48 h of 1 ng/ml TNFα + 10 U/ml INFγ insult. A Comparison of MBP expression in TNFα+INFγ or TNFα+INFγ+QTP treated differentiating OLs. 
OLs were immunostained for MBP (green) and nuclei stained with DAPI (blue). B, C The dose–response relationships and curves were determined 
and scaled to DMSO (0 % and no insult (100 %). The EC50 values for QTP were calculated to be 157 nM (n = 4, mean ± SEM) for cellular viability and 
125 nM (n = 4, mean ± SEM) for OL differentiation. D, E Viability and OL differentiation raw values of negative control DMSO and positive control 
QTP demonstrate the reproducibility of QTP protection from cytokine toxicity (n = 13, mean ± SEM). Coefficient of variation (CV) values for cell 
viability were 6.14 and 7.92 % and for OL differentiation were 19.16 and 17.21 % for DMSO and QTP, respectively. CV values <20 % were considered 
in the acceptable range
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conditions, such as those that would prevail in an MS 
lesion.
There are a number of advantages of adapting this assay 
for the purpose of screening compound libraries for com-
pounds that protect OLs from toxic insult. The robust-
ness, scale and reproducibility are amenable to HTS drug 
discovery. The assay uses minimally-passaged primary 
rat cells, obviating the need to produce large numbers 
of OPCs either through multiple passages or by deriva-
tion from large-scale stem cell cultures. We designed the 
assay to preserve primary cell, in vivo-like characteristics 
in culture by limiting subculture to a single expansion. 
Thus, we avoided undesirable changes in cellular pheno-
type (e.g. gene expression and/or unstable karyotypes) 
which multiple cell passages may introduce [3, 17–19]. 
We have also demonstrated that additional endpoints 
combined within the same assay can introduce interest-
ing predictive cellular phenotypes. Although the OL pro-
tection assay could be scored using OL differentiation as 
an image-based endpoint for identification of drugs that 
support OL differentiation in the presence of inflamma-
tory mediators, we have demonstrated that OL viability 
is an endpoint that is highly predictive of differentiation 
(33 of 36 hit compounds). Viability can be rapidly and 
inexpensively assessed using alamarBlue®, permitting 
much higher throughput than the image-based OL differ-
entiation assays. Moreover, alamarBlue® reagent is easily 
removed, permitting subsequent staining and imaging for 
OL differentiation if desired.
It is important to note that we have only evaluated 
OL differentiation in the presence of just two cytokines, 
but this delineates just one of many relevant, potentially 
detrimental, cytokine combinations. This OL protection 
assay is highly flexible and should be useful for evaluat-
ing a wide variety of other factors, such as examining 
the effects of other cytokines known to be present in MS 
lesions (alone and in combination) and other inflamma-
tory mediators such as myelin debris/breakdown prod-
ucts that may have detrimental effects on OLs.
Confirmed hits group into multiple classes
In a companion screen of the NCC library using an OL 
differentiation assay (see [15]), we identified 27 hit com-
pounds capable of promoting the differentiation of OPCs 
into OLs. Twenty-two of these compounds also pro-
tected OLs from inflammatory cytokine insults (Table 1). 
Intriguingly, an additional 16 compounds were identified 
that specifically rescued OL differentiation and promoted 
survival from cytokine toxicity. We grouped these hit 
compounds into the following categories: (1) muscarinic 
acetylcholine signaling, selective estrogen receptor mod-
ulators (SERMs), tricyclic antidepressants, non-tricyclic 
antidepressants, adrenergic receptor signaling, which 
were hits in both the OL protection assay and the OL 
Fig. 4 Flow scheme of the cytokine OL protection assay. A primary O4‑positive OPCs were isolated for P6–P7 neonatal rat brains. A OPCs were 
expanded in flasks for 5–7 days in defined media supplemented with PDGF. B Expanded OPCs were plated in 96‑well plates in defined media sup‑
plemented with T3, but without PDGF. C Test compounds were added following a 24‑h incubation period followed 1 h later by addition of cytokine 
challenge (1 ng/ml TNFα+10 U/ml IFNγ). D After 48‑h culture, alamarBlue® (AB) is added and AB fluorescence used to determine viability and 
metabolic activity of the cells. After selection of hit compounds (>50 % of the positive control, 1.1 µM QTP), fresh compound from a new source was 
obtained and the dose response relationship and EC50 values of each compound were determined. Following AB read out of the dose response, 
cells were fixed, immunostained, and images quantified to determine OL differentiation (MBP expression)
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differentiation assay and (2) antidiabetic, anti-retroviral, 
lipoxygenase inhibitor, histamine H1 antagonists and the 
retinoids which were only identified in the OL protec-
tion screen (Table  1). Within these classes emerged hit 
compounds that have relevance to MS and may be repur-
posed for therapeutic use in the treatment of MS.
Relevance to multiple sclerosis
We chose to screen the NCC library because it is a small, 
focused FDA-approved set of compounds with great 
clinical potential. Additionally we chose to screen at mul-
tiple concentrations in hopes of identifying compounds 
that are more efficacious at lower concentrations. While 
this added time to the process, we felt that this increase 
in screening time was more than offset by rapid progress 
to clinical trials for any such identified drugs that are 
FDA-approved.
There are many examples where repurposed drugs are 
making an impact in the field of MS. A few of note are 
BG-12 (Tecfidera®), a modification of a psoriasis drug; 
fingolimod (Gilenya®), originally developed for trans-
plantation and alemtuzamab (Lemtrada™), originally an 
oncology drug. We found that a fair number of our hits 
aligned with current MS repositioning efforts in terms 
of patents, preclinical work, and clinical trials and are 
briefly cited here.
QTP, our positive control for OL protection, has been 
reported in the literature to provide protection from the 
development of EAE symptoms and cuprizone insult, 
both rodent models of demyelinating disease, as well as 
preventing myelin loss and promoting OL differentiation 
in vivo [20–24].
The SERMs represent a promising new class of com-
pounds that protect OLs from cytokine toxicity and 
promote OL differentiation. Modulation of the estrogen 
receptor has been demonstrated to be effective in pre-
venting demyelination in vivo and to stimulate differen-
tiation and remyelination [25–28]. Specifically, raloxifene 
(Evista®) was shown to be effective in suppressing EAE 
[29]. Additionally, the pregnancy hormone estriol 
Fig. 5 Analysis of the cytokine OL protection assay of the NCC compound library. A Dot plot representation of the entire high‑throughput screen‑
ing data set used to identify promoters OL survival. The mean response is indicated by the blue solid line. The black dotted line delineates the value of 
three standard deviations above the mean. The red dotted line in delineates the ≥50 % positive control selection criteria. B Scatter plot representa‑
tion of the high‑throughput screening assay window. Using the QTP/DMSO ratio as the window of OL survival, the ratio of the positive (QTP) to 
negative (DMSO) controls is depicted in the scatterplot. The red line delineates the mean average ratio value for the entire NCC library screen = 1.3. 
The numbers above the scatter indicate the coefficient of variation (CV) for each plate. CV values <20 ± 5 were considered in the acceptable range. 
Each point is an average value from each screening plate (n = 4 wells, mean ± SEM). Inset depicts consistency of cytokine insult for the entire library 
with a mean average value of 1.4. C An overlapping representation of raw AB values of DMSO and QTP for each library screening plate. The inset 
depicts a statistical analysis of the raw AB values for the entire NCC library. D Summary tally of hits from the NCC library screen
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(Trimesta™), has shown efficacy in a clinical trial of MS 
reducing the lesion numbers and volumes [30]. This indi-
cates that modulation of the estrogen receptor pathway 
may be a viable target for OL differentiation and protec-
tion. Interestingly, sexual dimorphism has been noted 
within OL preparations with OLs derived from males 
and females separately responding differently to sex hor-
mones [31]. Our OL preparations were derived from ran-
domly selected P7 rat pups and therefore the response to 
some sex hormone signaling pathways may show differ-
ences from OLs isolated from one sex or the other.
A number of hits that we identified are covered in pat-
ents for oligodendrocyte directed differentiation. Notably 
trifluoperazine (Stelatzine®), benztropine (Cogentin®), 
ipatropium (Atrovent®), and clemastine (Tavist®), (US 
20140038949 A1) are patented for the use of neurotrans-
mitter receptor modulating agents for inducing OL dif-
ferentiation, as well as methods for treating subjects with 
such agents in a demyelinating disease.
Other hits have been evaluated or will soon be tested in 
human MS trials. QTP (Seroquel XR®), an antipsychotic 
approved for schizophrenia is currently in clinical trials 
to determine tolerability to people with RRMS and pro-
gressive MS (Clinicaltrials.gov identifier: NCT02087631). 
Selective serotonin re-uptake inhibitors (SSRIs) such as 
nitalapram (Celexa®) and escitalopram (Lexapro®) have 
also been in human MS trials. Nitalapram is one of three 
other SSRIs tested as an add-on with fingolimod, a cur-
rent immunomodulatory treatment for MS (REGAIN 
Trial NCT01436643) in RRMS patients with depression. 
Escitalopram, has been in a study to test improvement 
of depression in patients of MS or ALS (NCT00965497). 
Donepezil (Aricept®), used as a treatment for demen-
tia, has been used in a study to improve cognitive dys-
function in MS patients (NCT00315367) [32–34]. 
Oxybutynin (Ditropan XL®) is used currently in symp-
tom management for MS to treat overactive bladder in 
MS (SONIC trial NCT00629642). Clemastine fumarate 
(Tavist®) originally approved as a first-generation antihis-
tamine, is active in a current study to assess the drug as 
a remyelinating agent is RRMS patients (ReBUILD trial 
NCT02040298).
In preclinical studies, some of the compounds we iden-
tified as having protective properties show great promise 
in MS. The peroxisome proliferator-activated receptor 
gamma agonist, pioglitazone (Actos®—a drug used for 
diabetes), shows protective effects in the brain, delays 
onset and severity in rodent EAE models [35, 36] and is 
used as an add-on therapy for RRMS for treatment of 
nerve pain [37]. MK886, a lipoxygenase inhibitor, may 
be a useful therapeutic disease modifying treatment in 
MS, and it has been demonstrated to attenuate neuron 
inflammation, motor dysfunction and axonal damage in 
the mouse cuprizone-induced demyelination model [38]. 
Retinoic acid (Vesanoid®), an anti-cancer chemotherapy 
drug, has been cited to have a protective role in  vitro 
against neuro-inflammatory insults in vitro [39].
The antihistamines, hydroxyzine (Atarax®) and 
meclizine (Antivert®), identified from the OL protection 
screen are currently used for symptom management in 
MS. Hydroxyzine is used for alleviation of sensory symp-
toms in MS and cited in a published pilot clinical trial in 
MS patients [40]. Meclizine, used to treat vertigo, motion 
sickness and nausea, also treats those symptoms MS, as 
well as vomiting and dizziness symptoms.
To our knowledge, the remainder of our confirmed hits 
has not been tested in any demyelinating diseases. Future 
studies should focus on testing these compounds both 
in vitro with human cells as well as in vivo models of MS.
Conclusion
Here, we have described a large-scale primary cell-based 
drug discovery OL protection assay, with paradigms 
relevant to the MS environment and performed with 
industry rigor. We hope that other groups will find this 
assay helpful for comprehensively examining the effects 
of these factors on oligodendrocyte differentiation and 
health, and for developing drug screens that more closely 
mimic the pathology of the MS lesion.
Methods
High glucose Dulbecco’s Modified Eagle Medium 
(DMEM), Neurobasal medium (NB), Earle’s Balanced 
Salt Solution (EBSS), l-glutamine, Fetal Bovine Serum 
(FBS), penicillin/streptomycin, sodium pyruvate, diami-
dino-2-phenylindole, dilactate (DAPI) were purchased 
from Life Technologies (Carlsbad, CA, USA). Nor-
mal goat serum, forskolin, triiodothyronine (T3, thy-
roid hormone), vitamin B12, hydrocortisone, d-biotin, 
apotransferrin, putrescine, progesterone, sodium sele-
nite, poly-d-lysine (PDL), recombinant human (rh) insu-
lin, bovine serum albumin, N-acetyl-l-cysteine, sodium 
phosphate (mono- and dibasic), sodium chloride, tris 
base, l-lysine, sodium azide, tunicamycin and DMSO 
were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Trace elements B, Dulbecco’s Phosphate Buffer Saline 
(dPBS) and trypsin 0.05  %-EDTA were purchased from 
Mediatech, Inc. (Manassas, VA, USA). Human cerulo-
plasmin was purchased from EMD Millipore (Billerica, 
MA, USA). Recombinant rat (rr)CNTF, rrIFNγ, rrTNFα, 
rhNT-3 and rhPDGF-AA were purchased from Pepro-
Tech (Rock Hill, NJ, USA). DNase, papain and ovomucoid 
inhibitor were purchased from Worthington Biochemical 
Corporation (Lakewood, NJ, USA). Paraformaldehyde 
solution was purchased from Electron Microscopy Sci-
ence (Hatfield, PA). alamarBlue® (AB) was purchase from 
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AbD Serotech (Killington, UK). Falcon TC 96-well plates 
were purchase from Corning (Corning, NY). Additional 
file 4: Table S3 lists the primary antibodies and their dilu-
tions used in this study.
Compounds
All compounds in the NIH Clinical Collection (NCC) 
library were supplied in DMSO at 10  mM in 96-well 
plates. Hit compounds were purchased as powders 
and stock solutions were dissolved in DMSO to 10 mM 
(see Additional file  3: Table S2 for complete listing of 
compounds).
Isolation and expansion of neonatal rat OPCs
All animal work was carried out in strict accordance 
with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of 
Health. The protocol was approved by the Institutional 
Use and Care and Use Committee at the Molecular Med-
icine Research Institute (Sunnyvale, CA). Animals used 
for OPC isolation in these studies were euthanized by 
decapitation.
OPCs from brains of P6–P7 Sprague–Dawley rat pups 
(Charles River, Wilmington, MA, USA) were enriched by 
immunopanning as previously described [41]. Briefly, sin-
gle cell suspensions were obtained from papain-digested 
neonatal brains and depleted of mature glial cells by suc-
cessive panning with RAN-2- and GalC-coated plates, 
followed by enrichment for OPCs using O4-coated 
plates.
In vitro expanded OPCs were used in toxicity and 
cytokine protection assays. Acutely enriched OPCs were 
seeded into PDL-coated tissue culture flasks at 1000–
2000 cells/cm2 in differentiation media (DMEM, 100 U/
ml Penicillin/100  µg/ml Streptomycin, 2  mM  l-Glu-
tamine, 1  mM Na Pyruvate, 5  µg/ml Insulin, 5  µg/
ml  N-acetyl-l-cysteine, 1× Trace Elements B, 10  ng/
ml d-Biotin, 100  µg/ml BSA, 100  µg/ml apo-Transfer-
rin, 16 µg/ml Putrescine, 60 ng/ml Progesterone, 40 ng/
ml Sodium Selenite 5 ng/ml Forskolin, 10 ng/ml CNTF, 
1 ng/ml NT-3) supplemented with 10 ng/ml PDGF-AA. 
Proliferating OPCs were fed every 2–3 days and supple-
mented with 2–3× concentration of PDGF as needed 
to prevent OPC differentiation. After 6–7 days of prolif-
eration, OPCs were harvested by trypsinization, plated 
into PDL-coated 96-well Falcon plates and centrifuged 
at 200×g to facilitate cell attachment, survival, and even 
distribution of cells.
Oligodendrocyte protection assay
Expanded OPCs were plated at 10,000 cells/well in dif-
ferentiation media supplemented with 40 ng/ml T3 and 
incubated for 24 h at 37 °C, 10 % CO2 prior to addition of 
test compounds. Adjusted concentrations of NCC library 
compounds were added to triplicate wells to account 
for toxicity. One hour after addition of test compounds, 
10 Units/ml IFNγ + 1 ng/ml TNFα were added and cul-
tures were incubated for 48 h. Controls were added in six 
replicate wells, negative control = 0.1 % DMSO; positive 
controls = no insults (no IFNγ and no TNFα) or 1.1 μM 
QTP. A 1:10 dilution of AB was added to each well, incu-
bated 4 h at 37 °C, 10 % CO2 and fluorescence measured 
as above. In some experiments, following AB quantifi-
cation, cells were fixed with 4  % paraformaldehyde and 
immunostained for MBP expression as described below.
Immunofluorescence staining and imaging
Following compound treatment, media was removed 
leaving  50 μl/well using an ELx405 microplate washer 
(BioTek, Winooski, VT, USA), the automated plate 
washer was also used for all subsequent washing steps 
during the staining. Cells were fixed for 14 min with 4 % 
paraformaldehyde at room temperature (RT). Follow-
ing fixation, plates were washed with 1  ml PBS leaving 
50  μl/well behind. Cells were then incubated in block-
ing buffer (10  % normal goat serum (NGS) diluted in 
antibody buffer: 150  mM NaCl, 50  mM Tris Base, 1  % 
BSA, 100  mM  l-lysine, 0.04  % sodium azide, pH 7.4), 
with 0.4 % Triton X-100 for 1 h at RT, then stained over-
night at 4  °C with rat anti-MBP antibodies (Additional 
file  4: Table S3) diluted in blocking buffer with 0.08  % 
Triton X-100. The cells were washed and incubated with 
secondary antibodies and 0.3 μM DAPI for 1  h at RT. 
After a final wash, 100 μl of PBS was added to each well 
and plates imaged. Secondary antibody alone controls 
showed little to no background staining. Images were 
captured with a Nikon Eclipse TE-2000-U microscope, 
Zyla cMOS megapixel camera (ANDOR Technology, 
Belfast, UK), fitted with an automated stage controlled 
by NIS Elements AR software 4.0 (Melville, NY, USA). 
An air 10× lens was used to capture 2 images per well 
with 16 bit resolution, 2560  ×  2160 pixels. Images for 
each assay run were captured using identical camera set-
tings. Images were exported as TIFF files for analysis and 
quantification.
Image quantification
TIFF files were analyzed using custom algorithms created 
with IN Cell Investigator Developer Toolbox (GE Health 
Sciences, Piscataway, NJ, USA). For cytokine protection 
assay, two images were analyzed per well and the data 
from triplicate wells was combined and averaged (total 
of six images per test condition). The overall amount of 
MBP expression/cell was quantified in each image by cal-
culating the density × area of MBP staining, and normal-
izing to the total number of DAPI-stained nuclei in the 
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same field. The calculated extent of MBP expression (OL 
differentiation) was then scaled to internal plate nega-
tive (0.1 % DMSO, set to 0) and positive controls (40 ng/
ml T3 set to 100 %) to generate percent OL differentia-
tion scores relative to the efficacy of positive control. For 
the cytokine protection assay, the positive controls were 
either no insult or 1.1 μM QTP. This analysis consistently 
generated quantitatively similar results when scaled to 
internal plate negative and positive control wells.
Relative EC50 analysis
EC50 values were obtained by fitting the data to a sigmoi-
dal dose–response curve-fitting function (Prism, Graph-
Pad, San Diego, CA, USA). Serial dilutions of eight to ten 
different concentrations with three or four data points 
per concentration were used for curve fitting. Experi-
ments were repeated at least two times.
Statistical methods
For all experiments, assuming normal distribution, two-
tailed t tests were used to evaluate comparisons between 
two groups and ANOVA was used when more than two 
groups were compared. For the quantitative analysis of 
in vitro differentiation, ANOVA with Bonferroni or Dun-
nett correction was used.
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